Axial Therapeutics will use a new research grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance its experimental therapy for Parkinson’s disease, AX-5006, from ongoing preclinical studies into a first clinical trial in humans. The company is conducting a series of preclinical studies…
People with Parkinson’s disease who are experiencing cognitive decline may show weaker low-frequency brain waves on an electroencephalogram (EEG), a recording of the brain’s electrical activity, according to a recent study. Brain waves recorded at the front part of the brain were linked to measures of cognitive decline and…
A grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) will allow Icometrix — a company focused on artificial intelligence (AI) solutions for treating disease — to further advance its work on early biomarkers of Parkinson’s in brain magnetic resonance imaging (MRI) scans. “With this research, we…
Inhibikase Therapeutics, which is recruiting up to 120 untreated Parkinson’s disease patients across the U.S. to test its oral therapy IkT-148009, announced that its 201 trial program just dosed its first participant. The Phase 2 trial (NCT05424276) is assessing the safety and tolerability of IkT-148009 versus a…
Acorda Therapeutics has entered into an agreement with Chance Pharmaceuticals for Inbrija (levodopa inhalation powder), a medication used to treat symptoms during off episodes in Parkinson’s disease, to become available in China. Parkinson’s is a growing problem in China due to the country’s aging population; by…
A once-daily 200 mg dose of IkT-148009, Inhibikase Therapeutics‘ investigational therapy for Parkinson’s disease, reached steady levels in the body after four days without causing any serious side effects in healthy volunteers. The company plans to include this dose in its ongoing Phase 2 study (NCT05424276) in…
The U.S. Food and Drug Administration (FDA) has requested more information about the specialized pump used to administer ABBV-951 (foslevodopa/foscarbidopa), an under-the-skin formulation of levodopa/carbidopa, before it will consider approving the therapy for motor fluctuations in people with advanced Parkinson’s disease. The agency’s complete response letter comes 10…
IMAC Holdings and Brain Scientific have agreed to merge to offer solutions that cover the spectrum of care for neurological diseases, starting from diagnosis all the way through to treatment. The collaboration will focus mainly on disease management for people with Parkinson’s disease, Alzheimer’s disease, and…
People with idiopathic Parkinson’s disease have significantly higher blood levels of neurofilament light chain (NfL) — a biomarker of nerve cell damage — than those whose Parkinson’s is associated with mutations in the LRRK2 gene, a study showed. This difference, however, held true only for the early stages of disease,…
Microglia, the brain’s resident immune cells, may contribute to Parkinson’s disease by releasing tiny vesicles filled with alpha-synuclein — the protein that builds up to toxic levels in Parkinson’s — a mouse study suggests. This release, which was associated with greater nerve cell damage and worse motor function, was…
Get regular updates to your inbox.
